GLPG-2451/GLPG-2222/GLPG-2737

N/A

Report date: 2025/07/31 17:26:20

Base Information

Drug NameGLPG-2451/GLPG-2222/GLPG-2737

Drug Alias NameGLPG-2451+GLPG-2222+GLPG-2737GLPG-2222/GLPG-2737/GLPG-2451ABBV-2451+ABBV-2222+ABBV-2737GLPG-2737/GLPG-2451/GLPG-2222GLPG-2451+galicaftor+GLPG-2737 +[6]

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionCystic fibrosis transmembrane conductance regulator modulators

TargetsCystic fibrosis transmembrane conductance regulator

Therapy Area/IndicationsCystic Fibrosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumBulgariaSweden +[8]

CombinationsYes ABBV-2451 Galicaftor ABBV-2737

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesGalapagos Nv

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGalapagos Nv

Active IndicationsN/A

Inactive IndicationsCystic Fibrosis

Other Information

ATC CodeN/A